Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

✍ Scribed by Bartlett, J B; Michael, A; Clarke, I A; Dredge, K; Nicholson, S; Kristeleit, H; Polychronis, A; Pandha, H; Muller, G W; Stirling, D I

• Book ID: 109997932
• Publisher: Nature Publishing Group
• Year: 2004
• Tongue: English
• Weight: 193 KB
• Volume: 90
• Category: Article
• ISSN: 0007-0920
• DOI: 10.1038/sj.bjc.6601579